Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

117.10 -1.97 (-1.65%)

Official Closing Price Updated: 7:00 PM EDT, Apr 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	7,392,034
Open	119.15
Bid (Size)	116.75 (200)
Ask (Size)	117.99 (100)
Prev. Close	119.07
Today's Range	116.75 - 119.36
52wk Range	73.31 - 125.14
Shares Outstanding	2,531,374,696
Dividend Yield	2.90%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

3 Reasons We Love Merck (MRK)

April 20, 2026

Over the past six months, Merck has been a great trade, beating the S&P 500 by 32%. Its stock price has climbed to $118.94, representing a healthy 37.8% incr...

Via StockStory

Better Pharma Dividend Stock: Novartis vs. Merck ↗

April 17, 2026

Both are great stocks to buy in the current environment, but which one is the better bet?

Via The Motley Fool

Performance

YTD	+10.0%	+10.0%
1 Month	+1.2%	+1.2%
3 Month	+7.0%	+7.0%
6 Month	+35.7%	+35.7%
1 Year	+50.4%	+50.4%

More News

Tech Powerhouse: S&P 500 Eyes 12.6% Growth as AI Revolution Enters Second Gear

April 14, 2026

Via MarketMinute

Merck & Co. Inc. (NYSE:MRK) Offers a Durable Dividend Backed by Strong Earnings ↗

April 09, 2026

Via Chartmill

The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)

April 14, 2026

Via Finterra

1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

April 14, 2026

Via StockStory

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

Via Finterra

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

April 13, 2026

From Daiichi Sankyo

Via Business Wire

1 Momentum Stock on Our Buy List and 2 We Question

April 13, 2026

Via StockStory

Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗

April 12, 2026

Via The Motley Fool

Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis

April 09, 2026

Via MarketMinute

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasdaq - DAWN)

April 09, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue

April 09, 2026

Via Finterra

Why Terns Pharmaceuticals Stock Rocked the Market in March ↗

April 08, 2026

Via The Motley Fool

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

April 07, 2026

From Merck & Co., Inc.

Via Business Wire

You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗

April 07, 2026

Via The Motley Fool

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

Via MarketMinute

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

April 02, 2026

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

April 02, 2026

From Merck & Co., Inc.

Via Business Wire

The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future

April 01, 2026

Via Finterra

Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

April 01, 2026

From Merck & Co., Inc.

Via Business Wire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

Via MarketMinute

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

Via Finterra

Merck Just Made a Big Bet on a New Cancer Growth Engine ↗

March 31, 2026

Via MarketBeat

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

March 30, 2026

From Merck & Co., Inc.

Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?

Yes, Merck & Co is publicly traded.

What exchange does Merck & Co trade on?

Merck & Co trades on the New York Stock Exchange

What is the ticker symbol for Merck & Co?

The ticker symbol for Merck & Co is MRK on the New York Stock Exchange

What is the current price of Merck & Co?

The current price of Merck & Co is 117.10

When was Merck & Co last traded?

The last trade of Merck & Co was at 04/20/26 07:00 PM ET

What is the market capitalization of Merck & Co?

The market capitalization of Merck & Co is 296.42B

How many shares of Merck & Co are outstanding?

Merck & Co has 296B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.